Patents Issued in July 4, 2019
  • TREATMENT OF DISEASE WITH N-ACETYL KYNURENINE
    Publication number: 20190201360
    Abstract: The invention provides a method, composition and kit for treating T-cell mediated diseases, degenerative joint diseases or diseases mediated by platelet activating factor (PAF) comprising administering to an animal in need thereof, an effective amount a pharmaceutical composition containing N-acetyl-kynurenine (NAK) or pharmaceutically acceptable salts thereof as the active ingredient.
    Type: Application
    Filed: August 25, 2017
    Publication date: July 4, 2019
    Inventors: David BAR-OR, Leonard T. RAEL, Raphael BAR-OR
  • Methods and compositions for the treatment of diverticulosis
    Publication number: 20190201361
    Abstract: The present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis. In a method aspect, the present invention provides a method of treating diverticulosis. The method includes ingestion of 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diverticulosis.
    Type: Application
    Filed: February 11, 2019
    Publication date: July 4, 2019
    Inventor: Yutaka Niihara
  • Compositions for Diagnosis and Treatment of Anemia
    Publication number: 20190201362
    Abstract: Compositions including a fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to anemic conditions, are provided, including compositions and methods for treating anemic conditions such as hemolytic anemia and anemia of chronic disease, and other related conditions.
    Type: Application
    Filed: February 5, 2019
    Publication date: July 4, 2019
    Applicant: The United States of America as represented by the Secretary of the Navy
    Inventors: Stephanie Venn-Watson, Mark Baird
  • OILS WITH ANTI-INFLAMMATORY ACTIVITY CONTAINING NATURAL SPECIALIZED PRORESOLVING MEDIATORS AND THEIR PRECURSORS
    Publication number: 20190201363
    Abstract: The present invention encompasses oils that have anti-inflammatory or resolution-stimulating activity that contain or are enriched with Specialized Proresolving Mediators (SPM) or SPM precursors, which originate from an oil obtained from organisms containing long chain omega-3 polyunsaturated fatty acids, such as fish, crustaceae, algae, and mollusks. The invention also encompasses a method for the production of these oils, and the utilization of the oils for nutritional supplements, pharmaceutical formulations, and cosmetic formulations, which can be employed for treating an inflammatory condition.
    Type: Application
    Filed: March 8, 2019
    Publication date: July 4, 2019
    Inventors: Gerhardus Lucas Bannenberg, Charles Nicholas Serhan, Fernando Moreno Egea
  • PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND NICOTINIC ACID AND METHODS OF USING SAME
    Publication number: 20190201364
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising eicosapentaenoic acid and/or derivatives thereof and nicotinic acid, to methods of manufacturing such compositions, and to therapeutic methods for treating carious diseases and disorders.
    Type: Application
    Filed: March 12, 2019
    Publication date: July 4, 2019
    Inventor: Mehar Manku
  • ALPHA- AND GAMMA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20190201365
    Abstract: The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, having the structure:
    Type: Application
    Filed: February 15, 2019
    Publication date: July 4, 2019
    Applicant: The Research Foundation for The State University of New York
    Inventors: Iwao Ojima, Dale Deutsch, Martin Kaczocha, William T. Berger, Robert Rizzo, Trent E. Balius
  • KETONE BODIES AND KETONE BODY ESTERS AS BLOOD LIPID LOWERING AGENTS
    Publication number: 20190201366
    Abstract: The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic ?-hydroxybutyrate or D-?-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic ?-hydroxybutyrate or ?-hydroxybutyrate, esters of D-?-hydroxybutyrate, oligomers of D-?-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject.
    Type: Application
    Filed: November 29, 2018
    Publication date: July 4, 2019
    Inventors: Kieran Clarke, Richard Lewis Veech
  • PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES
    Publication number: 20190201367
    Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.
    Type: Application
    Filed: September 28, 2018
    Publication date: July 4, 2019
    Inventors: Tarek A. Zeidan, Scott Duncan, Christopher P. Hencken, Thomas Andrew Wynn, Carlos N. Sanrame
  • CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER
    Publication number: 20190201368
    Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.
    Type: Application
    Filed: March 6, 2019
    Publication date: July 4, 2019
    Inventors: Henrik NILSSON, Florian SCHOENHARTING, Bernd W. MUELLER, Joseph R. ROBINSON
  • PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYL FUMARATE FOR ADMINISTRATION AT A LOW DAILY DOSE
    Publication number: 20190201369
    Abstract: The present invention relates to pharmaceutical compositions containing dimethyl fumarate (DMF), More specifically, the present invention relates to a pharmaceutical composition for oral use in treating hyperproliferative, inflammatory or autoimmune disorders by administering a low daily dosage in the range of 410 mg±5% or 400 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet.
    Type: Application
    Filed: March 6, 2019
    Publication date: July 4, 2019
    Inventors: Christin GALETZKA, Chris RUNDFELDT, Roland RUPP, Peder M. ANDERSEN
  • BISMUTH(III) COMPOUNDS AND METHODS THEREOF
    Publication number: 20190201370
    Abstract: The present disclosure relates to a pharmaceutical composition comprising: (a) ?-lactam antibiotics and (b) a metallo-?-lactamases (MBLs) inhibitor. The inhibitor relates to Bi(III) compounds or the pharmaceutically acceptable salts thereof. The present patent also provides methods of making Bi(III) compounds or the pharmaceutically acceptable salts thereof. Also provided is a method for treating MBLs-producing bacterial infection using a metal replacement mechanism.
    Type: Application
    Filed: January 8, 2019
    Publication date: July 4, 2019
    Inventors: Hongzhe SUN, Richard Yi Tsun KAO, Runming WANG, Tsz Pui LAI, Hongmin ZHANG, Hongyan LI
  • BISMUTH-THIOLS AS ANTISEPTICS FOR EPITHELIAL TISSUES, ACUTE AND CHRONIC WOUNDS, BACTERIAL BIOFILMS AND OTHER INDICATIONS
    Publication number: 20190201371
    Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.
    Type: Application
    Filed: July 31, 2018
    Publication date: July 4, 2019
    Inventor: Brett Hugh James Baker
  • LIPOSOMAL PREPARATION AND METHODS OF TREATMENT
    Publication number: 20190201372
    Abstract: Pharmaceutical preparations comprising cannabinoid resins encapsulated in liposomes are provided. The preparations are characterised by particular molar ratios of carboxyl containing cannabinoids to their decarboxylated counterparts. Also provided are methods of preparing the pharmaceutical preparations and their use in the treatment of disease or disorders.
    Type: Application
    Filed: April 7, 2017
    Publication date: July 4, 2019
    Inventor: William MCKAY
  • INHIBITION OF CANCER CELL MOTILITY
    Publication number: 20190201373
    Abstract: Provided herein are compositions and methods for inhibiting cancer cell motility and/or metastasis. In particular embodiments, KBU2046 (or an analog thereof) and one or more additional therapies (e.g., cancer therapies (e.g., hormone therapies and chemotherapies) are provided to inhibit cancer cell motility, inhibit metastasis, and/or treat cancer (e.g., prostate cancer, lung cancer, breast cancer, colon cancer, etc.).
    Type: Application
    Filed: March 19, 2019
    Publication date: July 4, 2019
    Inventors: Raymond C. Bergan, Karl A. Scheidt, Li Xu
  • METHODS OF PREVENTING PROGRESSION TO TYPE 2 DIABETES MELITUS
    Publication number: 20190201374
    Abstract: The present invention provides compositions and methods for delaying or preventing progression to type 2 diabetes mellitus in individuals with prediabetes and metabolic syndrome.
    Type: Application
    Filed: July 31, 2018
    Publication date: July 4, 2019
    Inventors: Wesley DAY, Barbara TROUPIN
  • METHODS AND COMPOSITIONS FOR DELIVERING MYCOPHENOLIC ACID ACTIVE AGENTS TO NON-HUMAN MAMMALS
    Publication number: 20190201375
    Abstract: The present disclosure provides methods and compositions for modified delivery of mycophenolic acid active agents, including mycophenolate sodium, in canine subjects. Presently disclosed methods and compositions are useful, for example, to treat autoimmune diseases, blood disorders, and immune rejection related to transplant or graft procedures.
    Type: Application
    Filed: September 7, 2018
    Publication date: July 4, 2019
    Inventors: Michael KLOTSMAN, Padmaja SHIVANAND, Wayne H. Anderson, Gayatri SATHYAN
  • Method for Treating or Preventing Fatty Acid Binding Protein 3 Induced B-amyloid Aggregation Diseases
    Publication number: 20190201376
    Abstract: A method for treating or preventing fatty acid binding protein 3 induced ?-amyloid aggregation diseases is disclosed, comprising administering a pharmaceutical composition to a subject in need, where in the pharmaceutical composition comprises artemisinin.
    Type: Application
    Filed: December 3, 2018
    Publication date: July 4, 2019
    Inventors: Jung-Yaw LIN, Su-Chang LIN
  • METHODS AND COMPOSITIONS FOR TREATMENT OF LIPID STORAGE DISORDERS
    Publication number: 20190201377
    Abstract: Treating subjects having a lipid storage disorder with a composition comprising a PKC activator, such as bryostatins, bryologs, and polyunsaturated fatty acids. Accordingly, the present disclosure provides methods for treating human subjects suffering from lipid storage disorders, such as Niemann-Pick disease, by administering PKC activators. The present disclosure provides, according to certain embodiments, methods comprising administering to a subject with Niemann-Pick Type C disease a pharmaceutically effective amount of bryostatin 1.
    Type: Application
    Filed: January 15, 2019
    Publication date: July 4, 2019
    Inventors: Yiannis A. IOANNOU, Lawrence ALTSTIEL, David R. CROCKFORD, Sathapana KONGSAMUT
  • PHARMACEUTICAL COMPOSITIONS AND METHODS
    Publication number: 20190201378
    Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.
    Type: Application
    Filed: March 11, 2019
    Publication date: July 4, 2019
    Inventor: Steven Hoffman
  • BIS-AMINO ACID BASED COMPOUND AND USE THEREOF
    Publication number: 20190201379
    Abstract: Compositions comprising bis(tryptophan) derivatives are provided that act as antimicrobials. Also provided are methods for reversing antibiotic resistance in a bacterium, or recovering or enhancing antimicrobial activity of an antibiotic against a variety of microbes, by co-administration with a bis(tryptophan) derivative.
    Type: Application
    Filed: June 20, 2017
    Publication date: July 4, 2019
    Inventors: George W GOKEL, Joseph W MEISEL, Mohit B PATEL
  • SPIROCYCLIC COMPOUNDS
    Publication number: 20190201380
    Abstract: Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.
    Type: Application
    Filed: March 15, 2019
    Publication date: July 4, 2019
    Inventors: Peter Qinhua Huang, Mehmet Kahraman, Deborah Helen Slee, Kevin Duane Bunker, Chad Daniel Hopkins, Joseph Robert Pinchman, Sunny Abraham, Rakesh Kumar Sit, Daniel Lee Severance
  • COMPOSITIONS FOR CRYOPRESERVATION AND METHODS OF USE THEREOF
    Publication number: 20190201381
    Abstract: Providedherein are compositions for cryopreservation of mammalian cells, tissues, and organs. The compositions include a necroptosis inhibitor compound and a Bax channel inhibitor compound. Provided herein are also methods of use of the compositions, for treating, preventing, inhibiting, or reducing the incidence of cellular plasticity, or necroptosis or necrosis, of a plurality of cells, wherein the cells are brought into contact with the composition.
    Type: Application
    Filed: December 31, 2018
    Publication date: July 4, 2019
    Applicant: EVERGREEN BIOSCIENCES
    Inventors: Jason DICTENBERG, Pavel ISEROVICH
  • METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
    Publication number: 20190201382
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: March 19, 2019
    Publication date: July 4, 2019
    Applicant: Genentech, Inc.
    Inventors: Andrew POLSON, Shang-Fan YU, Yu-Waye CHU, Michael WENGER
  • Apparatus and Methods for Preventing or Treating Failure of Hemodialysis Vascular Access and Other Vascular Grafts
    Publication number: 20190201383
    Abstract: This invention is a prosthetic device generally placed on the outside surface of the vessel or graft which then elutes antiproliferative drugs or agents from a drug-eluting matrix material. Methods of perivascular antiproliferative drug administration also are disclosed.
    Type: Application
    Filed: March 8, 2019
    Publication date: July 4, 2019
    Inventors: Sriram S. Iyer, Nicholas N. Kipshidze, Victor V. Nikolaychik
  • 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS
    Publication number: 20190201384
    Abstract: The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
    Type: Application
    Filed: June 16, 2017
    Publication date: July 4, 2019
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Mary-Margaret Zablocki
  • APILIMOD FOR USE IN THE TREATMENT OF RENAL CANCER
    Publication number: 20190201385
    Abstract: The present disclosure relates to methods for treating renal cancer with apilimod and related compositions and methods.
    Type: Application
    Filed: December 19, 2018
    Publication date: July 4, 2019
    Inventors: Neil Beeharry, Sophia Gayle, Sean Landrette, Paul Beckett, Chris Conrad, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein
  • DOSAGE REGIMEN OF MDM2 INHIBITOR FOR TREATING CANCERS
    Publication number: 20190201386
    Abstract: The present invention provides a method for treating a cancer in a subject in need thereof, comprising administering a specific MDM2 inhibitor to the subject according to a specific dosage regimen and a pharmaceutical composition for use in treating a cancer according to the dosage regimen. The present invention also provides a method for treating liposarcoma in a subject in need thereof, comprising administering a specific MDM2 inhibitor to the subject and a pharmaceutical composition for use in treating liposarcoma, comprising the MDM2 inhibitor.
    Type: Application
    Filed: March 6, 2019
    Publication date: July 4, 2019
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Ngai-chiu Archie TSE, Shengli CAI
  • METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS
    Publication number: 20190201387
    Abstract: The present invention provides, inter alia, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway inhibitor therapy. Also provided are methods for identifying a subject having cancer who would benefit from therapy with an ERK inhibitor and methods for inhibiting phosphorylation of RSK in a cancer cell that is refractory or resistant to a non-ERK MAPK pathway inhibitor.
    Type: Application
    Filed: May 22, 2017
    Publication date: July 4, 2019
    Inventors: Saurabh Saha, Dean Welsch, Gary Decrescenzo, Jeffrey Roix
  • METHOD OF TREATING C3 GLOMERULOPATHY
    Publication number: 20190201388
    Abstract: Methods of treating a human suffering from or susceptible to C3 glomerulopathy comprising administering to the human an effective amount of a C5aR antagonist are provided.
    Type: Application
    Filed: November 8, 2018
    Publication date: July 4, 2019
    Inventor: Petrus BEKKER
  • HEAT SHOCK PROTEINS AND CHOLESTEROL HOMEOSTASIS
    Publication number: 20190201389
    Abstract: Provided herewith are bioactive agents that increase the intracellular concentration and/or activity of one or more heat shock proteins, including Hsp70, for use in the treatment of a disease associated with dysregulation of cholesterol homeostasis.
    Type: Application
    Filed: April 10, 2017
    Publication date: July 4, 2019
    Inventors: Thomas Kirkegaard Jensen, Elina Ikonen, Burcin Gungor
  • PHARMACEUTICAL COMPOSITION COMPRISING MINERALOCORTICOID RECEPTOR ANTAGONIST AND USE THEREOF
    Publication number: 20190201390
    Abstract: Provided are a pharmaceutical composition comprising a mineralocorticoid receptor antagonist and use thereof. When the pharmaceutical composition is orally administered to a patient having chronic kidney disease in need thereof, the effective and safe AUC ranges from 188 ng*h/mL to 3173 ng*h/mL, with bioavailability of 50% or more in mammals. When the pharmaceutical composition is orally administered at a daily dose of 0.1 to 1.0 mg to treat chronic kidney disease, the AUC is controlled at a safe and effective level.
    Type: Application
    Filed: September 22, 2017
    Publication date: July 4, 2019
    Applicant: KBP BIOSCIENCES CO., LTD.
    Inventors: Zhenhua HUANG, Xiaocui GUO
  • PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
    Publication number: 20190201391
    Abstract: Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.
    Type: Application
    Filed: July 26, 2018
    Publication date: July 4, 2019
    Inventors: Gerald YAKATAN, James BERG, Laura E. POPE, Richard A. SMITH
  • USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF AUTOIMMUNE DISORDERS
    Publication number: 20190201392
    Abstract: The embodiments described herein include methods and formulations for treating autoimmune disorders. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
    Type: Application
    Filed: December 18, 2018
    Publication date: July 4, 2019
    Inventor: Bruce Chandler May
  • LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF INFLAMMATION MEDIATED CONDITIONS
    Publication number: 20190201393
    Abstract: The embodiments described herein include methods and formulations for treating viruses and diseases that are exacerbated by inflammatory responses in the body. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
    Type: Application
    Filed: December 18, 2018
    Publication date: July 4, 2019
    Inventor: Bruce Chandler May
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER
    Publication number: 20190201394
    Abstract: Compositions and methods relating to induction of cell death such as in cancer cells are disclosed. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds in connection with modification of procaspases such as procaspase-3 are disclosed. In various embodiments, the compounds and compositions are capable of activation of procaspase-3.
    Type: Application
    Filed: December 21, 2018
    Publication date: July 4, 2019
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Paul J. Hergenrother, Karson S. Putt, Quinn P. Peterson, Valerie Fako
  • SLEEP IMPROVING AGENT
    Publication number: 20190201395
    Abstract: The present invention provides a heat shock protein expression-inducing agent, more specifically, a heat shock protein expression-inducing agent comprising a compound represented by formula (I): wherein R is a lower alkyl, phenyl, or hydroxyphenyl, or a salt thereof.
    Type: Application
    Filed: May 26, 2017
    Publication date: July 4, 2019
    Applicants: AMINO UP CHEMICAL CO., LTD., OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Kazunori GOTO, Jun NAKAHIGASHI, Atsuya SATO, Yosuke HIRAYAMA, Moeri HORIKOSHI, Noriyuki KOUDA, Syoichiro INOUE, Ikutaro SATO, Manami KATO
  • TREATMENT OF CANCERS HAVING ALTERATIONS WITHIN THE SWI/SNF CHROMATIN REMODELING COMPLEX
    Publication number: 20190201396
    Abstract: This disclosure provides compositions and methods of treating cancer by inhibiting histone methyltransferases alone or in combination by synergistically inhibiting a histone demethylase, or a histone deacetylase (HDAC), or a bromodomain (BRD)-containing protein, or a B-Raf kinase. In particular, the cancers have deficient of SWUSNF chromatin remodeling complexes because of mutations in one or more of the complex's subunit members.
    Type: Application
    Filed: September 7, 2017
    Publication date: July 4, 2019
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: David E. FISHER, Qing Yu WENG, Shinichiro KATO
  • METHODS OF TREATING OCULAR CONDITIONS
    Publication number: 20190201397
    Abstract: Described herein are methods and pharmaceutical formulations for treating ocular conditions.
    Type: Application
    Filed: April 6, 2017
    Publication date: July 4, 2019
    Applicant: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael ACKERMANN, James LOUDIN, Kenneth J. MANDELL
  • SOLUBILIZED COMPOSITIONS FOR CONTROLLED PROLIFERATION OF STEM CELLS / GENERATING INNER EAR HAIR CELLS USING A GSK3 INHIBITOR: I
    Publication number: 20190201398
    Abstract: The present invention relates to compositions and methods of inducing the self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair cells.
    Type: Application
    Filed: December 20, 2018
    Publication date: July 4, 2019
    Inventors: Christopher LOOSE, Will MCLEAN, Megan HARRISON, Michael R. JIROUSEK
  • COMPOSITIONS AND METHODS FOR TREATING INSOMNIA
    Publication number: 20190201399
    Abstract: In the present invention, compound such as (1R,2S)-2-(((2,4-dimethylpyrimidin-5-yl)oxy)methyl)-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide have been found to be potent orexin receptor antagonists, and may be useful in the treatment of sleep disorders such as insomnia, as well as for other therapeutic uses.
    Type: Application
    Filed: January 23, 2019
    Publication date: July 4, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Margaret MOLINE, Gina PASTINO, Yurie AKIMOTO, Yasuhiro ZAIMA, Nobuya SUZUKI, Nobuo YOSHIDA
  • ALDOSE REDUCTASE INHIBITORS AND USES THEREOF
    Publication number: 20190201400
    Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.
    Type: Application
    Filed: March 5, 2019
    Publication date: July 4, 2019
    Inventors: Andrew WASMUTH, Donald W. LANDRY, Shi Xian DENG, Banavara L. MYLARI, Ravichandran RAMASAMY, Ann Marie SCHMIDT
  • COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AND METHODS OF USE
    Publication number: 20190201401
    Abstract: In one aspect, methods of treating bacterial infections are described herein employing compounds having more than one target for antibacterial activity. Additionally pharmaceutical compositions comprising such compounds are also described.
    Type: Application
    Filed: August 1, 2018
    Publication date: July 4, 2019
    Inventors: Zemer Gitai, James Martin, Hsin-Jung Li, Max Wilson, Hahn Kim
  • Compositions and Methods for the Treatment of Prader-Willi Syndrome
    Publication number: 20190201402
    Abstract: The invention provides pharmaceutical compositions and methods of use thereof for treating Prader-Willi syndrome. More specifically, the invention provides pharmaceutical compositions that when administered inhibit the G9a driven methylation of histone H3 lysine 9.
    Type: Application
    Filed: May 17, 2017
    Publication date: July 4, 2019
    Inventors: Yong-hui Jiang, Yuna Kim, Hyeong-min Lee, Jian Jin, Bryan L. Roth
  • PYRROLOPYRIMIDINE COMPOUND
    Publication number: 20190201403
    Abstract: The present application relates to the field of pharmaceutical chemistry, and in particular, to a pyrrolopyrimidine compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the pyrrolopyrimidine compound represented by general formula (I), pharmaceutical compositions and an application of the pyrrolopyrimidine compound in treating diseases mediated by Janus Kinase.
    Type: Application
    Filed: December 15, 2015
    Publication date: July 4, 2019
    Inventors: Li Zhu, Dengming Xiao, Yuandong Hu, Liguang Dai, Xiaowei Duan, Yinghui Sun, Yong Peng, Fansheng Kong, Hong Luo, Yongxin Han, Ling Yang, Shanchun Wang
  • THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    Publication number: 20190201404
    Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.
    Type: Application
    Filed: March 8, 2019
    Publication date: July 4, 2019
    Inventors: András KOTSCHY, Zoltán Szlávik, Márton Csékei, Attila Paczal, Zoltán Szabó, Szabolcs Sipos, Gábor Radics, Ágnes Proszenyák, Balázs Bálint, Alain Bruno, Olivier Geneste, James Edward Paul Davidson, James Brooke Murray, I-Jen Chen, Françoise Perron-Sierra
  • PEMETREXED FORMULATIONS
    Publication number: 20190201405
    Abstract: The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C. The present invention is also directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable for at least about 24 months when stored at 2° C. to 8° C.
    Type: Application
    Filed: March 8, 2019
    Publication date: July 4, 2019
    Inventors: Feng-Jing Chen, Steven L. Krill
  • N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20190201406
    Abstract: The invention relates to N-(substituted-phenyl)-sulfonamide compounds, which are extremely useful as inhibitors of protein kinases (e.g. PERK kinase) and accordingly can be used for the treatment of cell proliferative disorders, such as cancer, or diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.
    Type: Application
    Filed: June 19, 2017
    Publication date: July 4, 2019
    Applicant: Nerviano Medical Sciences S.R.L.
    Inventors: Simona Bindi, Davide Carenzi, Ilaria Motto, Maurizio Pulici
  • FORMULATIONS OF VILOXAZINE
    Publication number: 20190201407
    Abstract: Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.
    Type: Application
    Filed: March 8, 2019
    Publication date: July 4, 2019
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Michael L. VIEIRA, Austin B. HUANG, Padmanabh P. BHATT
  • 6,7-DIALKOXY QUINAZOLINE DERIVATIVES AND METHODS OF TREATING DRUG RESISTANT AND OTHER TUMORS
    Publication number: 20190201408
    Abstract: Methods of inhibiting a receptor tyrosine kinase in a subject in need thereof. Methods of inhibiting the growth of a tumor cell in a subject in need thereof. Methods of treating pancreatic cancer in a subject in need of treatment for pancreatic cancer. Methods of treating HER2 positive breast cancer in a subject in need of treatment for HER2 positive breast cancer. Methods of treating drug resistant non-small cell lung cancer in a subject in need of treatment for drug resistant non-small cell lung cancer. Each of these methods can include administering to the subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 11, 2019
    Publication date: July 4, 2019
    Inventors: Bhujanga rao ADIBHATLA KALI SATYA, Ramanadham JYOTHI PRASAD, Bollepalli NAGESHWARA RAO, Nannapaneni VENKAIAH CHOWDARY
  • COMBINATION THERAPY
    Publication number: 20190201409
    Abstract: Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a second agent selected from a Bruton tyrosine kinase (BTK) inhibitor, a Bcl-2 inhibitor, an EZH2 inhibitor and a combination thereof to a patient.
    Type: Application
    Filed: September 18, 2017
    Publication date: July 4, 2019
    Inventor: Daniel P. GOLD